Aging and Disability Resource Center/No Wrong Door System COVID-19 Vaccine Access Supplemental Funding, 18287-18289 [2021-07208]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 66 / Thursday, April 8, 2021 / Notices
By direction of the Commission.
April J. Tabor,
Secretary.
Use of Funds
[FR Doc. 2021–07217 Filed 4–7–21; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Aging and Disability Resource Center/
No Wrong Door System COVID–19
Vaccine Access Supplemental Funding
Announcement Type: Initial.
Statutory Authority: The statutory
authority for grants under this funding
opportunity is contained in Title II of
the Older Americans Act of 1965 (OAA)
[as amended through P.L. 116–131] (42
U.S.C. 3012). Title II Section 202b(8),
the Coronavirus Aid, Relief, and
Economic Security (CARES) Act of
2020, and the Coronavirus Response
and Relief Supplemental
Appropriations Act, 2021. The Centers
for Disease Control and Prevention has
the authority under Section 301 of the
Public Health Service Act and Division
M, Consolidated Appropriations Act,
2021, Public Law 116–260.
Catalog of Federal Domestic
Assistance (CFDA) Number: 93.048.
DATES: The deadline for submission of
the supplemental funding request is
11:59 p.m. EST April 9, 2021.
khammond on DSKJM1Z7X2PROD with NOTICES
I. Funding Opportunity Description
This funding opportunity is to
support a new effort to get the nation’s
most vulnerable and at-risk seniors and
people with disabilities vaccinated.
Among some of the hardest to reach are
seniors and people with disabilities who
are unable to leave their home without
assistance or are homebound, are
socially isolated, live independently but
are medically fragile, or have cognitive
impairments. These individuals are at
particular risk because they may depend
on people coming into their homes to
provide services, including personal
care assistance. To assist in getting these
particularly vulnerable and at-risk older
adults and people with disabilities
vaccinated, the Biden-Harris
Administration has announced new
funding to reach these important
communities. The Administration for
Community Living, in partnership with
the Centers for Disease Control and
Prevention, provides this supplemental
funding opportunity specifically for
current Aging and Disability Resource
Center (ADRC)/No Wrong Door (NWD)
COVID–19 CARES Act funding grantees.
VerDate Sep<11>2014
16:53 Apr 07, 2021
Jkt 253001
These grants will provide assistance
with scheduling vaccine appointments,
transportation to vaccine sites, direct
support services needed to attend
vaccine appointments, connection to inhome vaccination options, and
education about the importance of
receiving the vaccine to older adults and
people with disabilities. In addition,
these grants will enable the aging and
disability networks to identify people
who are unable to independently travel
to vaccination sites and to provide
technical assistance to local health
departments on improving access to
vaccines for people with disabilities and
older adults.
This funding is specific to vaccine
access support and is encouraged to
support all ADRC/NWD partner
agencies and community based
organizations who may be able to reach
the most at-risk individuals. Grantees
are strongly encouraged to partner and
coordinate with state and local agencies
for this effort.
Expected activities to be performed
under this funding opportunity include:
• Public outreach and education
about COVID–19 vaccinations (e.g.
public announcements, targeted
marketing push, sharing information on
ADRC/NWD website) including ways to
address vaccination hesitancy.
• Individual outreach and awareness
(e.g., direct calls or in-person visits to
individuals who may be eligible).
• Vaccine registration support,
including through statewide websites,
211 or in-person.
• Transportation assistance to and
from vaccination sites, including
support during wait times at the
vaccination site.
• Support for unique vaccine
distribution methods including
arranging for in-home vaccinations for
individuals enrolled in state funded
long term services and supports (LTSS)
programs who may have difficultly
leaving the home.
• Addressing accessibility needs at
vaccination sites or post vaccination
recovery needs (e.g., coordinating with
AT programs.)
Key requirements for grantees under
this emergency FOA will include:
• Grantees are expected to regularly
participate in updates or touchpoints
with all ADRC/NWD partners and subgrantees to discuss progress, challenges,
and potential solutions related to
vaccination access for older adults and
people with disabilities.
• Grantees will report to ACL on a
semi-annual basis on challenges and
successes that have been experienced by
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
18287
all partners and sub-grantees and will
share ideas and receive technical
assistance to address challenges.
• Grantees will submit annual
progress reports on the activities
conducted, challenges, successes, and
lessons learned and provide a written
summary.
• Grantees are expected to spend
funds in reasonable timeframe. Grantees
who have not drawn funds from the
initial ADRC–COVID grant must explain
how they will spend this supplemental
funding in a prudent manner.
II. Award Information
1. Funding Instrument Type
These grants are discretionary,
supplemental grants, authorized by the
Centers for Disease Control and
Prevention under Section 301 of the
Public Health Service Act and Division
M, Consolidated Appropriations Act,
2021, Public Law 116–260 and
appropriated through the Coronavirus
Response and Relief Supplemental
Appropriations Act of 2021.
2. Anticipated Total Priority Area
Funding per Budget Period
The total available funding for this
opportunity is $26,000,000. ACL
intends to make available, under this
program announcement, supplemental
awards to ADRC–COVID grantees. The
period of performance for these grants
during which grant activities must occur
is estimated to be April 1, 2021 and is
projected to end on September 30, 2022.
ADRC–COVID grantees are eligible to
apply for and receive the amount of
funding in the table below:
State/territory
AK .........................................
AL .........................................
AR .........................................
AS .........................................
AZ .........................................
CA .........................................
CM ........................................
CO ........................................
CT .........................................
DC .........................................
DE .........................................
FL ..........................................
GA .........................................
GU ........................................
HI ..........................................
IA ..........................................
ID ..........................................
IL ...........................................
IN ..........................................
KS .........................................
KY .........................................
LA .........................................
MA ........................................
MD ........................................
ME ........................................
E:\FR\FM\08APN1.SGM
08APN1
Available
amount
$159,812
395,251
238,292
159,812
578,369
1,572,442
159,812
395,251
238,292
159,812
159,812
1,572,442
892,287
159,812
159,812
238,292
159,812
892,287
578,369
238,292
395,251
395,251
578,369
395,251
159,812
18288
Federal Register / Vol. 86, No. 66 / Thursday, April 8, 2021 / Notices
State/territory
MI ..........................................
MN ........................................
MO ........................................
MS ........................................
MT .........................................
NC .........................................
ND .........................................
NE .........................................
NH .........................................
NJ .........................................
NM ........................................
NV .........................................
NY .........................................
OH ........................................
OK .........................................
OR ........................................
PA .........................................
PR .........................................
RI ..........................................
SC .........................................
TN .........................................
TX .........................................
UT .........................................
VA .........................................
VT .........................................
WA ........................................
WI .........................................
WV ........................................
WY ........................................
Available
amount
892,287
395,251
578,369
238,292
159,812
892,287
159,812
159,812
159,812
578,369
238,292
238,292
1,572,442
892,287
395,251
395,251
1,572,442
395,251
159,812
395,251
578,369
1,572,442
238,292
578,369
159,812
578,369
395,251
238,292
159,812
III. Eligibility Criteria and Other
Requirements
1. Eligible Applicants for this award
are existing ADRC/NWD COVID–19
CARES Act grantees that received
funding on April 1, 2020.
2. Cost Sharing or Matching is not
required.
3. Grantees must submit a project
narrative through an online form and
complete an application in
GrantSolutions. Submission instructions
will be shared by the ACL Project
Officer. The online application form is
as follows:
ADRC/NWD COVID–19 Vaccine Access
Supplemental Funding Project Narrative
khammond on DSKJM1Z7X2PROD with NOTICES
Current Need
1. Briefly describe how your state/
territory’s ADRC/NWD System is
involved in increasing access to COVID–
19 vaccines and how these
supplemental funds will support these
activities. Please also share any
quantitative data (i.e. increased number
of volunteers by X number of
individuals, dedicated X number of staff
for vaccine rollout activities only,
increased staff hours by X amount,
increase in X number of calls, etc.) or
anecdotal stories that demonstrate
increase in demand for services and
support due to vaccine-related needs
(e.g., education and outreach,
scheduling vaccine appointments).
VerDate Sep<11>2014
16:53 Apr 07, 2021
Jkt 253001
Use of Funds
2. How many ADRC/NWD entities, or
sub-grantees, will be supported by this
funding?
2a. Please indicate the number of
anticipated ADRC/NWD entities or subgrantees by organization type. If an
entity/sub-grantee falls into more than
organization type, please use your
judgement to select the most
appropriate.
b AAA
b ADRC
b Advocacy partner
b Assistive Technology (AT)
b CIL/ILC
b Other Disability partner
b Traumatic Brain Injury (TBI) partners
b Veteran or Military partner
organizations
b Other CBO
b Other Local Government partner
b Tribal Partner
b University Partner
b Other (please explain)
3. Please select all of the following
ways the supplemental funding will be
used.
b Public outreach and education (e.g.
public announcements, targeted
marketing push, sharing information
on ADRC/NWD website)
b Individual outreach and awareness
(e.g., direct calls or in-person visits to
individuals who may be eligible)
b Vaccine registration, including
through statewide websites, 211 or inperson
b Transportation
b Vaccine distribution site
b Addressing accessibility needs (e.g.,
by coordinating with AT programs)
b Other, please describe
4. Do you anticipate this
supplemental funding meeting demand
in any of the following areas?
b Increasing number of volunteers
b Increasing number of staff for vaccine
access activities only
b Increasing staff hours
b Increasing call volume
b Increasing marketing activities (i.e.
developing outreach and education
materials, flyers, hosting virtual
townhalls, radio spots, infomercials,
etc.)
b Other (please explain)
5. Which of the following state-level
partners do you plan to coordinate with
for vaccine access activities?
b Developmental Disabilities Councils
b State Department or Division of
Disabilities
b State Assistive Technology Act
Programs
b State health department
b State Labor and Workforce
Development agency
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
b State Transportation agency
b State Medicaid Agency
b State Departments supporting
Military or Veteran programs
b University Centers for Excellence in
Developmental Disabilities (UCEDDs)
b Other (please explain)
6. Which of the following local
partners do you plan to coordinate with
for vaccine access activities?
b Area Agencies on Aging (AAAs)
b Aging and Disability Resource
Centers (ADRCs)
b Home health agencies
b Health Plans
b Local health departments
b Local transportation providers
b Housing and Urban Development
Service Coordinators
b Residential providers
b Employment centers
b Faith-based organizations
b Centers for Independent Living
(CILs)
b Other Disability partner
b Advocacy partners
b Traumatic Brain Injury (TBI) partners
b Tribal partners
b Other local government partner
b Other community based
organizations (CBOs)
b Other (please explain)
Demographics/Population Reach
7. Include a projection for number of
people served, by demographic, with
vaccine access support through this
supplemental funding:
b Individuals Age 60+
b Individuals Aged 21 to 59
b Individuals Age 20 and below
b Individuals with any type of
disabilities
b Individuals enrolled in state funded
long term services and supports
(LTSS) programs who may have
difficultly leaving the home
Technical Assistance Needs
8. In which of the following vaccinerelated technical assistance support do
you anticipate needing?
b Support in coordinating with public
health departments or other state/
local partners and agencies
b Addressing staff capacity and time to
meet demand
b Support for recruiting volunteers to
support staff
b Reaching people in priority groups
for vaccine access)
b Reaching minority and underserved
communities
b Addressing lack of access to
transportation services
b Addressing vaccine hesitancy
through education and other outreach
strategies
E:\FR\FM\08APN1.SGM
08APN1
Federal Register / Vol. 86, No. 66 / Thursday, April 8, 2021 / Notices
b Other, please explain
Direct inquiries regarding
programmatic issues to:
Ami Patel
Phone: 202.795.7376
Email: Ami.Patel@acl.hhs.gov
Group; Gene and Drug Delivery Systems
Study Section.
Date: June 7–8, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jain Krotz, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, (240) 672–8670,
jain.krotz@nih.gov.
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group;
Biobehavioral Medicine and Health
Outcomes Study Section.
Date: June 7–8, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mark A. Vosvick, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3110,
Bethesda, MD 20892, (301) 402–4128,
mark.vosvick@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 2, 2021.
Alison Barkoff,
Acting Administrator and Assistant Secretary
for Aging.
Dated: April 5, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–07208 Filed 4–7–21; 8:45 am]
[FR Doc. 2021–07250 Filed 4–7–21; 8:45 am]
BILLING CODE 4154–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Bioengineering
Sciences & Technologies Integrated Review
Name of Committee: National Institute on
Aging Special Emphasis Panel; Recruitment
4. DUNS Number
All grant applicants must obtain and
keep current a D–U–N–S number from
Dun and Bradstreet. It is a nine-digit
identification number, which provides
unique identifiers of single business
entities. The D–U–N–S number can be
obtained from: https://iupdate.dnb.com/
iUpdate/viewiUpdateHome.htm.
5. Intergovernmental Review
Executive Order 12372,
Intergovernmental Review of Federal
Programs, is not applicable to these
grant applications.
IV. Submission Information
1. Instructions for completing the
application will be available from the
ACL Project Officer.
2. Submission Dates and Times.
To receive consideration, applications
must be submitted by 11:59 p.m. Eastern
Time on April 09, 2021, through
www.GrantSolutions.gov.
khammond on DSKJM1Z7X2PROD with NOTICES
VII. Agency Contacts
VerDate Sep<11>2014
16:53 Apr 07, 2021
Jkt 253001
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
18289
and Retention for Alzheimer’s Disease
Diversity Genetic Cohorts in The Adsp
(Readd-Adsp).
Date: May 13, 2021.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Video Meeting).
Contact Person: Rajasri Roy, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Aging, National
Institutes of Health, Gateway Building
2W200, 7201 Wisconsin Avenue, Bethesda,
MD 20892, (301) 496–6477, rajasri.roy@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–07249 Filed 4–7–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Bone-Muscle
Signaling.
Date: April 28, 2021.
Time: 12:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Video Meeting).
Contact Person: Nijaguna Prasad, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Aging, National
Institutes of Health, 7201 Wisconsin Avenue,
Gateway Building, Suite 2W200, Bethesda,
MD 20892, (301) 496–9667,
nijaguna.prasad@nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Clinical
Trials R01.
E:\FR\FM\08APN1.SGM
08APN1
]]>Agencies
[Federal Register Volume 86, Number 66 (Thursday, April 8, 2021)]
[Notices]
[Pages 18287-18289]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-07208]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Community Living
Aging and Disability Resource Center/No Wrong Door System COVID-
19 Vaccine Access Supplemental Funding
Announcement Type: Initial.
Statutory Authority: The statutory authority for grants under this
funding opportunity is contained in Title II of the Older Americans Act
of 1965 (OAA) [as amended through P.L. 116-131] (42 U.S.C. 3012). Title
II Section 202b(8), the Coronavirus Aid, Relief, and Economic Security
(CARES) Act of 2020, and the Coronavirus Response and Relief
Supplemental Appropriations Act, 2021. The Centers for Disease Control
and Prevention has the authority under Section 301 of the Public Health
Service Act and Division M, Consolidated Appropriations Act, 2021,
Public Law 116-260.
Catalog of Federal Domestic Assistance (CFDA) Number: 93.048.
DATES: The deadline for submission of the supplemental funding request
is 11:59 p.m. EST April 9, 2021.
I. Funding Opportunity Description
This funding opportunity is to support a new effort to get the
nation's most vulnerable and at-risk seniors and people with
disabilities vaccinated. Among some of the hardest to reach are seniors
and people with disabilities who are unable to leave their home without
assistance or are homebound, are socially isolated, live independently
but are medically fragile, or have cognitive impairments. These
individuals are at particular risk because they may depend on people
coming into their homes to provide services, including personal care
assistance. To assist in getting these particularly vulnerable and at-
risk older adults and people with disabilities vaccinated, the Biden-
Harris Administration has announced new funding to reach these
important communities. The Administration for Community Living, in
partnership with the Centers for Disease Control and Prevention,
provides this supplemental funding opportunity specifically for current
Aging and Disability Resource Center (ADRC)/No Wrong Door (NWD) COVID-
19 CARES Act funding grantees.
Use of Funds
These grants will provide assistance with scheduling vaccine
appointments, transportation to vaccine sites, direct support services
needed to attend vaccine appointments, connection to in-home
vaccination options, and education about the importance of receiving
the vaccine to older adults and people with disabilities. In addition,
these grants will enable the aging and disability networks to identify
people who are unable to independently travel to vaccination sites and
to provide technical assistance to local health departments on
improving access to vaccines for people with disabilities and older
adults.
This funding is specific to vaccine access support and is
encouraged to support all ADRC/NWD partner agencies and community based
organizations who may be able to reach the most at-risk individuals.
Grantees are strongly encouraged to partner and coordinate with state
and local agencies for this effort.
Expected activities to be performed under this funding opportunity
include:
Public outreach and education about COVID-19 vaccinations
(e.g. public announcements, targeted marketing push, sharing
information on ADRC/NWD website) including ways to address vaccination
hesitancy.
Individual outreach and awareness (e.g., direct calls or
in-person visits to individuals who may be eligible).
Vaccine registration support, including through statewide
websites, 211 or in-person.
Transportation assistance to and from vaccination sites,
including support during wait times at the vaccination site.
Support for unique vaccine distribution methods including
arranging for in-home vaccinations for individuals enrolled in state
funded long term services and supports (LTSS) programs who may have
difficultly leaving the home.
Addressing accessibility needs at vaccination sites or
post vaccination recovery needs (e.g., coordinating with AT programs.)
Key requirements for grantees under this emergency FOA will
include:
Grantees are expected to regularly participate in updates
or touchpoints with all ADRC/NWD partners and sub-grantees to discuss
progress, challenges, and potential solutions related to vaccination
access for older adults and people with disabilities.
Grantees will report to ACL on a semi-annual basis on
challenges and successes that have been experienced by all partners and
sub-grantees and will share ideas and receive technical assistance to
address challenges.
Grantees will submit annual progress reports on the
activities conducted, challenges, successes, and lessons learned and
provide a written summary.
Grantees are expected to spend funds in reasonable
timeframe. Grantees who have not drawn funds from the initial ADRC-
COVID grant must explain how they will spend this supplemental funding
in a prudent manner.
II. Award Information
1. Funding Instrument Type
These grants are discretionary, supplemental grants, authorized by
the Centers for Disease Control and Prevention under Section 301 of the
Public Health Service Act and Division M, Consolidated Appropriations
Act, 2021, Public Law 116-260 and appropriated through the Coronavirus
Response and Relief Supplemental Appropriations Act of 2021.
2. Anticipated Total Priority Area Funding per Budget Period
The total available funding for this opportunity is $26,000,000.
ACL intends to make available, under this program announcement,
supplemental awards to ADRC-COVID grantees. The period of performance
for these grants during which grant activities must occur is estimated
to be April 1, 2021 and is projected to end on September 30, 2022.
ADRC-COVID grantees are eligible to apply for and receive the amount of
funding in the table below:
------------------------------------------------------------------------
Available
State/territory amount
------------------------------------------------------------------------
AK...................................................... $159,812
AL...................................................... 395,251
AR...................................................... 238,292
AS...................................................... 159,812
AZ...................................................... 578,369
CA...................................................... 1,572,442
CM...................................................... 159,812
CO...................................................... 395,251
CT...................................................... 238,292
DC...................................................... 159,812
DE...................................................... 159,812
FL...................................................... 1,572,442
GA...................................................... 892,287
GU...................................................... 159,812
HI...................................................... 159,812
IA...................................................... 238,292
ID...................................................... 159,812
IL...................................................... 892,287
IN...................................................... 578,369
KS...................................................... 238,292
KY...................................................... 395,251
LA...................................................... 395,251
MA...................................................... 578,369
MD...................................................... 395,251
ME...................................................... 159,812
[[Page 18288]]
MI...................................................... 892,287
MN...................................................... 395,251
MO...................................................... 578,369
MS...................................................... 238,292
MT...................................................... 159,812
NC...................................................... 892,287
ND...................................................... 159,812
NE...................................................... 159,812
NH...................................................... 159,812
NJ...................................................... 578,369
NM...................................................... 238,292
NV...................................................... 238,292
NY...................................................... 1,572,442
OH...................................................... 892,287
OK...................................................... 395,251
OR...................................................... 395,251
PA...................................................... 1,572,442
PR...................................................... 395,251
RI...................................................... 159,812
SC...................................................... 395,251
TN...................................................... 578,369
TX...................................................... 1,572,442
UT...................................................... 238,292
VA...................................................... 578,369
VT...................................................... 159,812
WA...................................................... 578,369
WI...................................................... 395,251
WV...................................................... 238,292
WY...................................................... 159,812
------------------------------------------------------------------------
III. Eligibility Criteria and Other Requirements
1. Eligible Applicants for this award are existing ADRC/NWD COVID-
19 CARES Act grantees that received funding on April 1, 2020.
2. Cost Sharing or Matching is not required.
3. Grantees must submit a project narrative through an online form
and complete an application in GrantSolutions. Submission instructions
will be shared by the ACL Project Officer. The online application form
is as follows:
ADRC/NWD COVID-19 Vaccine Access Supplemental Funding Project Narrative
Current Need
1. Briefly describe how your state/territory's ADRC/NWD System is
involved in increasing access to COVID-19 vaccines and how these
supplemental funds will support these activities. Please also share any
quantitative data (i.e. increased number of volunteers by X number of
individuals, dedicated X number of staff for vaccine rollout activities
only, increased staff hours by X amount, increase in X number of calls,
etc.) or anecdotal stories that demonstrate increase in demand for
services and support due to vaccine-related needs (e.g., education and
outreach, scheduling vaccine appointments).
Use of Funds
2. How many ADRC/NWD entities, or sub-grantees, will be supported
by this funding?
2a. Please indicate the number of anticipated ADRC/NWD entities or
sub-grantees by organization type. If an entity/sub-grantee falls into
more than organization type, please use your judgement to select the
most appropriate.
[square] AAA
[square] ADRC
[square] Advocacy partner
[square] Assistive Technology (AT)
[square] CIL/ILC
[square] Other Disability partner
[square] Traumatic Brain Injury (TBI) partners
[square] Veteran or Military partner organizations
[square] Other CBO
[square] Other Local Government partner
[square] Tribal Partner
[square] University Partner
[square] Other (please explain)
3. Please select all of the following ways the supplemental funding
will be used.
[square] Public outreach and education (e.g. public announcements,
targeted marketing push, sharing information on ADRC/NWD website)
[square] Individual outreach and awareness (e.g., direct calls or in-
person visits to individuals who may be eligible)
[square] Vaccine registration, including through statewide websites,
211 or in-person
[square] Transportation
[square] Vaccine distribution site
[square] Addressing accessibility needs (e.g., by coordinating with AT
programs)
[square] Other, please describe
4. Do you anticipate this supplemental funding meeting demand in
any of the following areas?
[square] Increasing number of volunteers
[square] Increasing number of staff for vaccine access activities only
[square] Increasing staff hours
[square] Increasing call volume
[square] Increasing marketing activities (i.e. developing outreach and
education materials, flyers, hosting virtual townhalls, radio spots,
infomercials, etc.)
[square] Other (please explain)
5. Which of the following state-level partners do you plan to
coordinate with for vaccine access activities?
[square] Developmental Disabilities Councils
[square] State Department or Division of Disabilities
[square] State Assistive Technology Act Programs
[square] State health department
[square] State Labor and Workforce Development agency
[square] State Transportation agency
[square] State Medicaid Agency
[square] State Departments supporting Military or Veteran programs
[square] University Centers for Excellence in Developmental
Disabilities (UCEDDs)
[square] Other (please explain)
6. Which of the following local partners do you plan to coordinate
with for vaccine access activities?
[square] Area Agencies on Aging (AAAs)
[square] Aging and Disability Resource Centers (ADRCs)
[square] Home health agencies
[square] Health Plans
[square] Local health departments
[square] Local transportation providers
[square] Housing and Urban Development Service Coordinators
[square] Residential providers
[square] Employment centers
[square] Faith-based organizations
[square] Centers for Independent Living (CILs)
[square] Other Disability partner
[square] Advocacy partners
[square] Traumatic Brain Injury (TBI) partners
[square] Tribal partners
[square] Other local government partner
[square] Other community based organizations (CBOs)
[square] Other (please explain)
Demographics/Population Reach
7. Include a projection for number of people served, by
demographic, with vaccine access support through this supplemental
funding:
[square] Individuals Age 60+
[square] Individuals Aged 21 to 59
[square] Individuals Age 20 and below
[square] Individuals with any type of disabilities
[square] Individuals enrolled in state funded long term services and
supports (LTSS) programs who may have difficultly leaving the home
Technical Assistance Needs
8. In which of the following vaccine-related technical assistance
support do you anticipate needing?
[square] Support in coordinating with public health departments or
other state/local partners and agencies
[square] Addressing staff capacity and time to meet demand
[square] Support for recruiting volunteers to support staff
[square] Reaching people in priority groups for vaccine access)
[square] Reaching minority and underserved communities
[square] Addressing lack of access to transportation services
[square] Addressing vaccine hesitancy through education and other
outreach strategies
[[Page 18289]]
[square] Other, please explain
4. DUNS Number
All grant applicants must obtain and keep current a D-U-N-S number
from Dun and Bradstreet. It is a nine-digit identification number,
which provides unique identifiers of single business entities. The D-U-
N-S number can be obtained from: https://iupdate.dnb.com/iUpdate/viewiUpdateHome.htm.
5. Intergovernmental Review
Executive Order 12372, Intergovernmental Review of Federal
Programs, is not applicable to these grant applications.
IV. Submission Information
1. Instructions for completing the application will be available
from the ACL Project Officer.
2. Submission Dates and Times.
To receive consideration, applications must be submitted by 11:59
p.m. Eastern Time on April 09, 2021, through www.GrantSolutions.gov.
VII. Agency Contacts
Direct inquiries regarding programmatic issues to:
Ami Patel
Phone: 202.795.7376
Email: [email protected]
Dated: April 2, 2021.
Alison Barkoff,
Acting Administrator and Assistant Secretary for Aging.
[FR Doc. 2021-07208 Filed 4-7-21; 8:45 am]
BILLING CODE 4154-01-P
